

In addition, please replace the computer readable form (CRF) of the Sequence Listing submitted on December 19, 1999, with the enclosed substitute CRF.

**REMARKS**

The specification has been amended to add the application serial number (page 1 of the attached substitute paper copy of the Sequence Listing), and has also been amended to explain the location of "n" and which residue "n" represents (page 2 of the attached substitute paper copy of the Sequence Listing).

Pursuant to 37 CFR §1.821(f), Applicant's undersigned attorney hereby certifies that the contents of the paper form and the computer readable form of the substitute Sequence Listing are the same.

No new matter has been introduced. Accordingly, Applicants respectfully request that this amendment be entered and that the application proceed to examination. If any issues remain, the Examiner is invited to call the undersigned attorney at (919) 541-8614 to discuss the case.

Respectfully submitted,

  
MAR 23 2000  
TECH CENTER 1600/2300  
Bruce Vrana  
Attorney for Applicants  
Registration No. 38,672

Novartis Agribusiness Biotechnology Research, Inc.  
P. O. Box 12257  
Research Triangle Park, NC 27709-2257  
Telephone: 919-597-3033

Date: March 14, 2000